An observational study in Bradycardia, sponsored by Medical University Innsbruck. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Medical University Innsbruck · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Bradycardia with a site in Austria — 7 open to participants now, 7 under way, none of them phase 3. Bradycardia · Austria.
Among the 26 studies in Bradycardia with a site in Austria, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2021, is one of 11 observational ones, and was the 19th registered.
317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.
Browse Bradycardia studies →7 of the 26 studies in Bradycardia with a site in Austria are open now. Recruiting first, the newest first:
Biotronik SE & Co. KG · Sites in Austria, Australia, Czechia and 10 more countries
Ages 18+
Biotronik, Inc. · Sites in Austria, United States, Australia and 5 more countries
Ages 18+
MicroPort CRM · Sites in Austria, Belgium, France and 5 more countries
Ages 18+
Karl Landsteiner University of Health Sciences · Sites in Austria
Ages 18+
Medtronic · Sites in Austria, United States, Australia and 32 more countries
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 51 Bradycardia studies recruiting now, 34 (67%) set no upper age limit and 9 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 257 across 127 observational studies indexed under Bradycardia.
Median enrollment 129 across the 15 interventional studies, 870 across the 11 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 26 have an industry lead sponsor. The 10 most frequent:
Medical University Innsbruck is the lead sponsor of 187 studies on the registry; 48 are open to participants now.
Medical University Innsbruck has 1 study filed under Bradycardia — fewer than ten, so there is no comparison to draw.
1 of the studies in Bradycardia with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07118358Biotronik, Inc.BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Bradycardia with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, non-interventional cohort study. It tests the hypothesis that
All forms of arrhythmias, sleep apnea during sleeping hours and physical activity using sensors in modern implanted pacemakers as well as autonomic imbalance measures will be correlated with the incidence and progression (within 5 years of follow-up) of common co-morbidities such as arterial hypertension, coronary artery disease, heart failure, COPD, peripheral artery disease, iron insufficiency. In a long follow up perspective major adverse cardiovascular events will be recorded and new risk scores will be developed, incorporating machine learning techniques.
Patients with pacemakers are usually above the age of 65 years, and suffer from common co-morbidities such as arterial hypertension, coronary artery disease, heart failure, COPD, peripheral artery disease, iron insufficiency, sleep disordered breathing, obesity and/or physical inactivity / de-conditioning.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
defined by a pacemaker-derived mean RDI ≥ 20/h in the first 12 months after enrollment
defined by PRD ≥ 5.75deg2 (native) and/or ≥ 3 deg2 (paced) assessed within the first 12 months of enrollment
defined by a pacemaker-derived mean daily physical activity level \< 2h in the first 12 months after enrollment
3P-MACE
death, myocardial infarction and/or stroke
Time frame: time to first event, follow up for 120 months
device-detected atrial fibrillation
first episode lasting more than 6 minutes or 24 hours
Time frame: time to first event, follow up for 120 months
device-detected atrial fibrillation
total burden
Time frame: after 1, 3, 5 years
device-detected sleep apnea
severity (RDI \< versus \> 20/h)
Time frame: after 1, 3, 5 years
device-detected sleep apnea
variation
Time frame: after 1, 3, 5 years
incidence of common opthalmological disease
in correlation to device-detected sleep apnea and device-detected atrial fibrillation
Time frame: assessed within the first year after study enrollment
Deterioration of lung function
conventional lung function testing
Time frame: after 5 years
Progression of subclinical peripheral artery disease
sonography
Time frame: after 5 years
Progression of subclinical peripheral artery disease
ABI
Time frame: after 5 years
QoL assessment
EQ-5D-5L
Time frame: after 5 years
Started Nov 2021 (actual). Primary completion is estimated for Dec 2041, 241 months after the start.
Of 73 observational studies under Bradycardia, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 96. This study's planned 241 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University Innsbruck →